



STUDY USING FOSCARNET IN HAEMATOLOGICAL PATIENTS



Authors: García Sanz E, Manso Manrique M, Santiago Prieto, E. Torralba Arranz A.

Hospital Universitario Puerta de Hierro Majadahonda. Madrid. Spain

making the difference in medication

DGI-065

BACKGROUND

Cytomegalovirus (CMV) commonly affects bone marrow transplant patients causing significant morbidity and mortality. Foscarnet is a broad spectrum antiviral agent, active against CMV, but not the treatment of choice.

PURPOSE

To know the reason for prescription, check the treatment efficacy and its adverse effects

MATERIALS AND METHODS

Retrospective study (2011). Data were obtained from patient clinical records and pharmacy database. We produced a database with information on demographics, underlying disease, indication, treatment duration, dosage, adverse effects and treatment results based on PCR viral load negativization. We also examined whether there had prior treatment with ganciclovir and the reason for the change, or the cause of not starting treatment with ganciclovir.


RESULTS

We found 12 patients (8 male), in the hematology department receiving foscarnet.



Medium age was 31.

The average length of treatment was 11,4 days. The treatment was effective in 11 patients (91.6%)

6 patients was not used prior ganciclovir (pancytopenia and problems with engraftment) 6 patients used prior ganciclovir, and change was by development of resistance (4), and haematological toxicity (2)



4 PATIENTS HAD NO TOXICITY



CONCLUSIONS

- Foscarnet is an effective alternative in the treatment of CMV infection in case of intolerance or lack of response to ganciclovir
- Worsening renal function is the most important adverse effect